Sep 14, 2022 · Approximately 13%–40% of patients with Crohn's disease (CD) show a primary loss of response to infliximab (IFX) therapy.
IDDF2021-ABS-0039 Identifying patients with crohn's disease ... - Gut
gut.bmj.com › content › Suppl_2
Conclusions The radiomic-clinical nomogram may be a promising tool to allow accurately identify CD patients at high risk of primary nonresponse to infliximab ...
Sep 14, 2022 · Approximately 13%–40% of patients with Crohn's disease (CD) show a primary loss of response to infliximab (IFX) therapy.
Dive into the research topics of 'Identifying patients with Crohn's disease at high risk of primary nonresponse to infliximab using a radiomic-clinical model'.
In this double‐center study, we developed and validated a computed tomography enterography (CTE)‐based radiomic signature (RS) for identification of CD patients ...
Jan 30, 2024 · Identifying patients with Crohn's disease at high risk of primary nonresponse to infliximab using a radiomic-clinical model. Int J ...
People also search for
Related health topics
For informational purposes only. Consult your local medical authority for advice.
Identifying patients with Crohn's disease at high risk of primary nonresponse to infliximab using a radiomic‐clinical model · Xue-hua Li, Yingkui Zhong, +18 ...
This study aimed to develop and validate a novel radiomic-clinical nomogram to identify CD patients at high risk of primary nonresponse to infliximab therapy.
Mar 13, 2024 · The first proposed pancreatic-related model predicts secondary loss of response for infliximab in Crohn's disease. • The model achieved ...
The radiomic-clinical nomogram may be a promising tool to allow accurately identify CD patients at high risk of primary nonresponse to infliximab therapy. Full ...